Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
With a market cap of 15.48B, Moderna(MRNA) trades at $39.20. The stock has a price-to-earnings ratio of -4.91.
On 2026-01-14, Moderna(MRNA) stock traded between a low of $33.78 and a high of $39.71. Shares are currently priced at $39.20, which is +16.0% above the low and -1.3% below the high.
Moderna(MRNA) shares are trading with a volume of 24.71M, against a daily average of 11.97M.
In the last year, Moderna(MRNA) shares hit a 52-week high of $45.40 and a 52-week low of $22.28.
In the last year, Moderna(MRNA) shares hit a 52-week high of $45.40 and a 52-week low of $22.28.
MRNA News
Moderna rallies after projecting better-than-expected 2025 sales Moderna rallied more than 15% on Tuesday after saying on Monday that its COVID-19 business did...
U.S. stocks were mixed, with the Dow Jones index falling around 250 points on Tuesday. Shares of Moderna Inc (NASDAQ:MRNA) rose sharply during Tuesday's sessio...
Moderna (MRNA) is up 12.9%, or $4.37 to $38.21. Claim 70% Off TipRanks Premium Published first on TheFly – the ultimate source for real-time, market-moving br...
Analyst ratings
65%
of 26 ratingsMore MRNA News
William Blair analyst Myles Minter has reiterated their neutral stance on MRNA stock, giving a Hold rating yesterday. Claim 70% Off TipRanks Premium Unlock hedg...
(RTTNews) - Moderna (MRNA) heads into 2026 with stronger finances and a crowded late-stage pipeline after an aggressive cost reset in 2025 and a slate of regula...
Moderna, Inc. (NASDAQ:MRNA) shares are volatile Monday after the company provided updates on its business and pipeline at the 44th Annual J.P. Morgan Healthcare...
Moderna, which has been bleeding money since 2023, said it expects to break even in 2028. Moderna said its COVID-19 business did better than expected last year...
Moderna (MRNA) has reiterated its target of up to 10% revenue growth in 2026, supported by a strategy to build a large seasonal vaccine franchise. “We remain f...
In early January 2026, Moderna reported positive Phase 3 data and submitted regulatory applications in the U.S., EU, Canada, and Australia for its mRNA-1010 sea...
Investors in Moderna Inc (Symbol: MRNA) saw new options begin trading today, for the February 27th expiration. At Stock Options Channel , our YieldBoost formula...